Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples
| Autor: | Daniel E. L. Promislow, Caitlin S. Latimer, Adrienne M. Wang, Benjamin R Harrison, Silvan R. Urfer, Warren Ladiges, Franco Guscetti, Sarah J Benbow, C. Dirk Keene, Brian C. Kraemer, Martin Darvas, Matt Kaeberlein |
|---|---|
| Přispěvatelé: | University of Zurich |
| Rok vydání: | 2019 |
| Předmět: |
Aging
Histology 10184 Institute of Veterinary Pathology amyloid β42 Neuropathology Disease lcsh:Geriatrics Phospho tau 03 medical and health sciences Technical Report 0302 clinical medicine Cortex (anatomy) medicine phospho-tau 030304 developmental biology 0303 health sciences phospho business.industry alzheimer’s disease 3. Good health lcsh:RC952-954.6 cortex medicine.anatomical_structure Preclinical testing 570 Life sciences biology luminex Tau Geriatrics and Gerontology business Neuroscience 030217 neurology & neurosurgery |
| Zdroj: | Pathobiology of Aging & Age-related Diseases, Vol 9, Iss 1 (2019) Pathobiology of Aging & Age Related Diseases |
| ISSN: | 2001-0001 |
| Popis: | A major obstacle for preclinical testing of Alzheimer’s disease (AD) therapies is the availability of translationally relevant AD models. Critical for the validation of such models is the application of the same approaches and techniques used for the neuropathological characterization of AD. Deposition of amyloid-β 42 (Aβ42) plaques and neurofibrillary tangles containing phospho-Tau (pTau) are the pathognomonic features of AD. In the neuropathologic evaluation of AD, immunohistochemistry (IHC) is the current standard method for detection of Aβ42 and pTau. Although IHC is indispensable for determining the distribution of AD pathology, it is of rather limited use for assessment of the quantity of AD pathology. We have recently developed Luminex-based assays for the quantitative assessment of Aβ42 and pTau in AD brains. These assays are based on the same antibodies that are used for the IHC-based diagnosis of AD neuropathologic change. Here we report the application and extension of such quantitative AD neuropathology assays to commonly used genetically engineered AD models and to animals that develop AD neuropathologic change as they age naturally. We believe that identifying AD models that have Aβ42 or pTau levels comparable to those observed in AD will greatly improve the ability to develop AD therapies. Abbreviations: Alzheimer’s disease (AD); amyloid β 42 (Aβ42); phospho-Tau (pTau); immunohistochemistry (IHC) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|